IRCT2017040332913N2
Recruiting
Phase 2
Response Evaluation of Muscle-Invasive Bladder Cancer treated With Concomitant Chemoradiation By Either Irradiation Plus Weekly Cisplatin Or Irradiation Plus Low Dose Gemcitabine By Conventional Fractionated Radiotherapy
Vice-Chancellor for Research of Iran University of Medical Sciences0 sites72 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Vice-Chancellor for Research of Iran University of Medical Sciences
- Enrollment
- 72
- Status
- Recruiting
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Primary carcinoma of the bladder (Transitional Cell Cancer) with
- •muscularis propria invasion diagnosed within 8 weeks of registration; clinical stage T2\-T4a, Nx or N0, M0 without hydronephrosis; the patient can tolerate systemic chemotherapy combined with pelvic radiotherapy and a radical cystectomy by joint agreement of the Urologist and Oncologist; The following laboratory tests that has been done within 4 weeks prior to registration on this study is as following: WBC greater than or equal to 4000, ANC greater than or equal to 1800, Hemoglobin greater than or equal to 10\.0, Platelets greater than or equal to 100,000, Creatinine clearance greater than or equal to 60ml/min, Serum creatinine of 1\.5 or less, If no, the creatinine clearance is greater than 60 ml/min and serum creatinine is no more than 1\.8 Serum bilirubin of less than or equal to 2\.0 mg%; No evidence of distant metastases, The patient has not received prior pelvic radiation therapy or chemotherapy, nor had cancers other than non\-melanoma skin cancer and early stage cancer of prostate or cervix; the patient has none of any of the severe, active co\-morbidities defined as following: Unstable angina and/or congestive heart failure, requiring hospitalization within the last 6 months, transmural myocardial infarction within the last 6 months, acute bacterial or
- •fungal infection requiring intravenous antibiotics at the time of registration, chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration; hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; acquired immune deficiency syndrome (AIDS) based upon current CDC definition; The patient has no known severe sensitivity reactions to the drugs used in the trial.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Clinical outcomes in non-muscle invasive bladder cancer: A global multisite chart review studyON-MUSCLE INVASIVE BLADDER CANCERC67Malignant neoplasm of bladderDRKS00020117Merck Sharp & Dohme Corp.129
Completed
Not Applicable
on-invasive evaluation of urinary bladder contractility and urethral resistance after ProACT treatment of stress urinary incontinence in men: a pilot study.involuntary urine loss due to increased abdominal pressure.stress urinary incontinence10004994NL-OMON34897Erasmus MC, Universitair Medisch Centrum Rotterdam50
Completed
Not Applicable
on-invasive evaluation of urinary bladder contractility and urethral resistance after ProACT treatment of stress urinary incontinence in men: a pilot study.stress urinary incontinenceurine stress incontinentieNL-OMON21192Erasmus Medical Center, Department of Urology50
Completed
Not Applicable
Identification of muscle-invasive bladder cancer patients who will not benefit from neoadjuvant chemotherapy using circulating tumor cells.muscle invasive bladder cancermuscle invasive bladder carcinoma1003836410004994NL-OMON45144Erasmus MC, Universitair Medisch Centrum Rotterdam320
Not yet recruiting
Not Applicable
Integrated Overactive Bladder Clinical Trial in clinical practice IIIbladder overactivityurgency1000499410038365NL-OMON38014Medisch Universitair Ziekenhuis Maastricht166